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Abstract
Introduction Interleukin-6 (IL-6) is thought to play a pathogenic
role in rheumatoid arthritis and synovium is a major source of IL-
6 release. We investigated the ability of retinoids to suppress IL-
6 expression in IL-1-stimulated synovial fibroblasts, with special
care to the contribution of retinoic acid receptor (RAR) and
retinoid X receptor (RXR) subtypes, and the implication of the
mitogen-activated protein kinase (MAPK) pathway.
Methods RAR-α, -β, and -γ and RXR-α, -β, and -γ levels were
determined by reverse transcription-quantitative polymerase
chain reaction (RT-qPCR) or Western blot in rat synovial
fibroblasts stimulated with 10 ng/mL of IL-1β. Stimulated levels
of IL-6 were assessed by RT-qPCR or immunoassays in the
presence or absence of 1 μM all-trans  retinoic acid (ATRA)
(RAR agonist) or 0.3 μM BMS-649 (RXR agonist). The
contribution of RAR subtypes was checked with selective
agonists or small interfering RNAs. The effect of ATRA on
upstream MAPK (p38 MAPK, c-Jun N-terminal kinase [JNK], and
extracellularly regulated kinase 1/2 [ERK1/2]) was assessed by
Western blot, and the contribution of the ERK1/2 pathway to the
activation of pro-inflammatory transcription factors was studied
by TransAm™ assays.
Results Synovial fibroblasts expressed all RAR and RXR
subtypes except RXR-γ. In IL-1-stimulated cells, ATRA, but not
BMS-649, reduced IL-6  expression whereas selective RAR
agonists were inactive. The inhibitory effect of ATRA on IL-6 was
not affected by the silencing of RAR subtypes. ATRA also
reduced the phosphorylation of ERK1/2, but not of p38 MAPK or
of JNK. The suppressive effect of ATRA on the activation of
activator protein-1 (AP-1) and nuclear factor-IL-6 (NF-IL-6) was
reproduced by the MEK1 (mitogen-activated protein
extracellularly regulated kinase kinase 1) inhibitor PD-98059,
whereas ATRA and PD-98059 had no effect on NF-κB
activation.
Conclusions Among RAR and RXR agonists, only ATRA
inhibited IL-1-induced IL-6 expression in rat synovial fibroblasts
by inhibiting ERK1/2 pathway and subsequent activation of AP-1
and NF-IL-6 independently of RAR.
Introduction
Retinoids are natural or synthetic analogs of vitamin A, includ-
ing all-trans retinoic acid (ATRA) and its 9-cis isomer (9-cis
RA). ATRA and other retinoids play a major role in a wide
range of physiological pathways such as cell proliferation,
embryogenesis, differentiation, morphogenesis, and inflamma-
tion (for a review, see [1]). Retinoids exert their functions
through their binding to the retinoic acid receptor (RAR) and
the retinoid X receptor (RXR), which belong to the subfamily B
(respectively, NR1B and NR2B) of the nuclear hormone
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receptors. Each receptor is divided into three subtypes, which
are referred as RAR-α, -β, or -γ and RXR-α, -β, or -γ and which
are encoded by separate genes [2]. After binding of retinoids,
RAR and RXR form a homodimer or a heterodimer and activate
the cellular machinery for an increased transcription rate. But
RAR and RXR can alternatively induce gene transrepression
by sequestering transcription factors such as activator protein-
1 (AP-1) or nuclear factor-interleukin-6 (NF-IL-6) without bind-
ing to DNA [2]. Based on the regulatory role of these transcrip-
tion factors in the control of many inflammatory mediators,
liganded RAR complexes can repress a broad spectrum of
genes, including inflammatory proteins, cytokines, or matrix
metalloproteases (MMPs) [3].
Rheumatoid arthritis (RA) is an immune-mediated inflammatory
disease characterized by a chronic inflammation of the syno-
vial membrane which organizes into an aggressive front of tis-
sue able to invade and destroy local articular structures [4].
Although the cause of RA remains unknown, it has been estab-
lished that cytokine networks play a pivotal role in the immuno-
inflammatory and destructive response of RA [5]. Besides
tumor necrosis factor-alpha (TNF-α) or IL-1, the pro-inflamma-
tory and pleiotropic cytokine IL-6 could have important activi-
ties in the context of pathogenesis of RA [6]. Hence, huge
amounts are found in the synovial fluid and tissue and in the
sera of arthritic patients [7], and IL-6 serum levels have been
correlated with the activity of the disease [6]. IL-6 is synthe-
sized and then secreted extensively by fibroblast-like synovio-
cytes from RA patients [8,9]. The synthesis is regulated mainly
by the transcription factors NF-IL-6, CAAT-enhancer-binding
protein (C/EBP)-β, AP-1, and nuclear factor-kappa-B (NF-κB)
[8,10,11], which are constitutively activated in RA synovial tis-
sue (for a review, see [12]) and have binding sites in the pro-
moter region of the IL-6 gene. Among possible pathogenic
roles, IL-6 activates T cells and macrophages, induces osteo-
clast differentiation, causes systemic inflammatory manifesta-
tions, and could promote angiogenesis [6]. As a
consequence, the blockade of IL-6 effects has emerged as a
new therapeutic approach to RA, and tocilizumab, a human-
ized anti-human IL-6 receptor monoclonal antibody, has suc-
cessfully entered the clinics (for a review, see [13]). These
clinical data have confirmed the pathological role of IL-6 in RA
(for a review, see [13]) and suggest that this second genera-
tion of anti-cytokine therapy may have therapeutical relevance
in patients who have a limited response to disease modifying
anti-rheumatic drugs or biological agents, such as inhibitors of
TNF-α [5].
Beside their successful use in the treatment of skin diseases
or cancer, retinoids were shown to be anti-inflammatory in sev-
eral animal models of RA. Thus, a decrease of cartilage
lesions, associated with a reduction of MMP-1 expression,
was reported in the paws of adjuvant arthritis (AA) rats treated
with 13-cis RA [14]. In the rodent collagen-induced arthritis
(CIA) model, ATRA improves the course of the disease and
reduces the production of inflammatory cytokines [15], and
Am-80 (RAR agonist) decreases anti-collagen II antibody lev-
els and improves joint swelling and bone destruction [16].
However, in contrast to its efficacy in the AA model, 13-cis RA
remained poorly effective in the rat CIA model [16]. Apart from
differences in the pathogenic mechanisms of animal models of
RA [17] or in the binding activity of retinoids to RAR subtypes,
these experimental data strongly suggest that the anti-arthritic
effect of RAR agonists is supported mainly by their ability to
reduce the immune response. The inflamed synovial tissue is a
major source of IL-6 production [18], and the blockade of IL-6
[19] or its deficiency [20] reduced the severity of experimental
arthritis by impairing the T-cell response. These data led us to
postulate that the ability of retinoids to inhibit IL-6 production
by activated synovial fibroblasts could have a major role in their
antiarthritic potency. Therefore, we compared the suppressive
properties of the RAR agonist ATRA and of the RXR agonist,
BMS-649, on IL-1-induced expression of IL-6 in rat synovial
fibroblasts and tried to elucidate the corresponding molecular
events with respect to the contribution of RAR/RXR subtypes
and signalling pathways.
First, we used compounds acting either on RAR or RXR, alone
or in combination, to demonstrate that the downregulation of
IL-6 was not dependent of RXR activation. Using mRNA
silencing of RAR subtypes and selective agonists of RAR-α, -
β, or -γ, we showed that the inhibitory potency of ATRA on IL-
6 was independent of RAR activation. Finally, we demon-
strated that the MEK1 (mitogen-activated protein extracellu-
larly regulated kinase kinase 1) inhibitor PD-98059
reproduced the ability of ATRA to reduce the IL-1-induced
phosphorylation of extracellularly regulated kinase 1/2 (ERK1/
2) and activation of AP-1 and of NF-IL-6, but not of NF-κB.
These data demonstrate that ATRA suppressed the IL-1-
induced production of IL-6 in an RAR-independent manner by
inhibiting the ERK1/2 pathway and subsequent activation of
AP-1 and NF-IL-6 in synovial fibroblasts.
Materials and methods
Synovial fibroblast isolation and culture
Rat synovial fibroblasts were obtained from synovium col-
lected aseptically from healthy Wistar male rats (130 to 150 g;
Charles River, L'Arbresle, France), killed under dissociative
anesthesia (ketamine [Rhône-Mérieux, Lyon, France] and ace-
promazine [Sanofi Santé Animale, Paris, France]) in accord-
ance with national animal care guidelines, after approval by our
internal ethics committee, as described before [21]. Cells
were cultured as monolayers in 75-cm2 flasks at 37°C in a
humidified atmosphere containing 5% of CO2, until the fourth
passage, in order to prevent any strong contamination by mac-
rophage-like cells and to obtain a homogenous population of
synovial fibroblasts. The cell phenotype was controlled by
measuring the mRNA level of the fibroblast-like markers syno-
violin and cadherin-11 [22] and of the macrophage-like marker
CD14 [23].Available online http://arthritis-research.com/content/10/6/R141
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Study design
The expression of IL-6 was studied in rat synovial fibroblasts
cultured under low fetal calf serum conditions and stimulated
with 10 ng/mL of rat recombinant IL-1β (R&D Systems, Lille,
France) in the presence or absence of a RAR agonist, ATRA
(Sigma-Aldrich, St. Louis, MO, USA), used at 1 μM and/or an
RXR agonist, BMS-649 (kindly provided by Bristol-Myers
Squibb Company, Princeton, NJ, USA), used at 0.3 μM. Selec-
tive agonists (kindly provided by Bristol-Myers Squibb Com-
pany) of RAR-α (BMS-753), RAR-β (BMS-453), or RAR-γ
(BMS-961) were used at 0.1 or 1 μM. All drugs were main-
tained in the dark before addition to the culture medium, at a
final concentration of 0.1% or 0.2% of dimethyl sulfoxide
(DMSO), at the same time as IL-1 stimulation. The contribution
of RAR subtypes to the effect of ATRA was investigated using
the RNA interference technology. The effect of ATRA on the
activation of mitogen-activated protein kinase (MAPK) path-
ways was studied in IL-1-stimulated cells by measuring the
phosphorylation of p38 MAPK, stress-activated protein
kinase/c-Jun N-terminal kinase (SAPK/JNK), or ERK1/2  by
Western blot after 5, 15, or 30 minutes, respectively. The
effect of ATRA and the possible contribution of ERK1/2 on IL-
1β-induced activation of NF-κB, NF-IL-6, or AP-1 were studied
by TransAm™ assays (Active Motif, Rixensart, Belgium).
Assay for synovial fibroblast viability
Cell viability was assessed by the mitochondria-dependent
reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) (Sigma-Aldrich) as described
before [24].
Gene-silencing experiment
For experiments of RAR subtype silencing, double-stranded
small interfering RNA (siRNA) corresponding to a region of
RAR-α (GCAGUUCGGAAGAGAUAGU), RAR-β
(CUAGCUACUGGCUUCAAGA), or RAR-γ (GCCUUCUUC-
CUUUACCUCC) mRNA was synthesized by Eurogentec
(Liege, Belgium). Transfection of synovial fibroblasts with 50
nM siRNA was performed during 24 hours using X-TremeG-
ENE reagent®  (Roche Molecular Biochemicals, Meylan,
France) in accordance with manufacturer recommendations.
Cells were then stimulated with IL-1β for 6 hours in the pres-
ence or absence (DMSO alone) of ATRA.
RNA extraction and reverse transcription-polymerase 
chain reaction analysis
After stimulation with IL-1β in the presence or absence
(DMSO alone) of RAR or RXR agonists, total RNA was
extracted from cell layers using an RNeasy extraction kit in
accordance with the recommendations of the manufacturer
(Qiagen, Courtabœuf, France), as described before [21]. The
mRNA levels for RAR-α, -β, or -γ, RXR-α, -β, or -γ, IL-6, and
ribosomal protein S29 (RP29) were quantified by real-time
quantitative polymerase chain reaction (PCR) in capillaries
with the Lightcycler™ technology (Roche Molecular Biochem-
icals). The reaction mixture was composed of cDNAs, SYBR
green master mix system® (Qiagen), and primer pairs specific
for the DNA fragments to be amplified. The sequences of the
primers used were IL-6 (sense: 5'-CCGGAGAGGAGACT-
TCACAG-3', anti-sense: 5'-CCGGAGAGGAGACT-
TCACAG-3', NM 012589, 161 base pairs [bp], 59°C), RAR-
α (sense: 5'-ACCAGATTACCCTTCTCAAGG-3', anti-sense:
5'-GGTACCGCGTGCAGATT-3', NM 031528, 65 bp, 58°C),
RAR-β  (5'-TCTTAATGAAAATCACAGATCTCCGC-3', anti-
sense: 5'-CCAGGAATTTCCATTTTCAAGG-3', XM 223843,
62 bp, 57°C), RAR-γ  (sense: 5'-AGTGCTATCTGCCT-
CATCT-3', anti-sense: 5'-TTGTCCACCTTCACCTTCTCG-
GGTTC-3', NM 001062412, 66 bp, 62°C), RXR-α  (5':
GAAGCGTACTGCAAACACAAG-3', anti-sense: 5'-
CAGCCGGAGCAGCAGCTTGG-3', NM 012805, 65 bp,
66°C),  RXR-β  (sense: 5'-CTTCATGTGCACAGAAACT-3',
anti-sense: 5'-TCTGTCAGCACCCGATCAAA-3', NM
206849, 68 bp, 55°C), RXR-γ  (sense: 5'-CTGCACCG-
GGCAGGGTGGAAT-3', anti-sense: 5'-CTGGACGGAAAC-
CGAGCGGTG-3', NM 031765, 65 bp, 66°C), and RP29
(sense: AAGATGGGTCACCAGCAGCTCTACTG-3', anti-
sense: 5'-AGACGCGGCAAGAGCGAGAA-3', NM 012876,
70 bp, 59°C).
The quantity of each cDNA was estimated by threshold cycle
(Ct), defined as the number of cycles corresponding to the
moment when the fluorescence, secondary to SYBR green
incorporation into double-stranded DNA, became detectable
at the end of the PCR elongation phase. At completion of PCR
cycling, a melting curve was performed in order to control the
specificity of each amplified product. Each experiment
included positive and negative reaction controls, and Ct values
were converted into nanograms of DNA using calibration
curves made of serial dilutions of known amounts of corre-
sponding purified PCR products. The transcript level of the
housekeeping gene RP29 was determined in parallel for each
sample, and data were expressed as the normalized ratio of
mRNA level of each gene of interest over the RP29 gene.
Measurement of IL-6 production
IL-6 secreted in culture supernatant after 24 hours of incuba-
tion was measured in nanograms per milliliter with commer-
cially available rat enzyme-linked immunosorbent assay
(ELISA) (R&D Systems, Abingdon, UK) with a limit of detection
of 21 pg/mL. The assay was not sensitive to soluble receptors
and no cross-reactivity was reported with other cytokines
(manufacturer's data). Positive controls were used in each
experiment.
Western blot analysis
For protein study, experiments were performed from 5 minutes
to 24 hours after IL-1β challenge. Cellular proteins were
extracted with 1× Laemmli blue (Sigma-Aldrich), as described
before [24], and electroblotted with RAR-α, RAR-β, RAR-γ,
RXR-α, RXR-β, or RXR-γ (1:2,000; Santa Cruz Biotechnology,Arthritis Research & Therapy    Vol 10 No 6    Kirchmeyer et al.
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Le Perray en Yvelines, France), phospho-ERK1/2 (P-ERK1/2),
phospho-p38 MAPK (P-p38 MAPK) (1:1,000; Cell Signaling
Technology, Inc., Danvers, MA, USA), phospho-SAPK/JNK (P-
JNK) (1:500; Cell Signaling Technology, Inc.), or β-actin
(1:4,000; Sigma-Aldrich). Detection of protein bands was
done by chemiluminescence with the Phototope Detection
system in accordance with the recommendations of the man-
ufacturer (Cell Signaling Technology, Inc.). Results were
expressed as the ratio of each protein of interest over β-actin,
used as internal control.
ELISA-based TransAm™ kit for NF-IL-6, NF-κB (p65), and 
AP-1 (c-Jun)
Synovial fibroblasts were preincubated for 1 hour with 10 μM
PD-98059 (inhibitor of ERK1/2; Sigma-Aldrich) or incubated
with 1 μM ATRA before stimulation for 30 minutes or 4 hours
with IL-1β. At corresponding times, nuclear extracts were pre-
pared with a commercially available kit according to the rec-
ommendations of the manufacturer (Active Motif), as
described before [24]. After protein quantification with a bicin-
choninic acid assay kit (BCA™ protein assay kit; Sigma-
Aldrich), nuclear extracts were checked for NF-IL-6, NF-κB
(p65), and AP-1 (c-Jun) activation using ELISA-based kits
(TransAm™). Briefly, 2 μg of nuclear proteins was added in a
volume of 20 μL to a well plate precoated with oligonucle-
otides (5'-GGGACTTTCC-3') corresponding to NF-κB
responsive element (RE), or (5'-GCAAT-3') corresponding to
NF-IL-6 RE, or (5'-TGAGTCA-3') corresponding to AP-1 RE.
Wells were then incubated with a primary antibody against
phosphorylated NF-κB (p65) (1:1,000), phosphorylated NF-
IL-6 (1:1,500), or phosphorylated AP-1 (c-Jun) (1:500). The
RE/NF-κB, NF-IL-6, or AP-1 antibody complex was revealed
by incubation with a secondary horseradish peroxidase-conju-
gated antibody. The amounts of NF-κB (p65), NF-IL-6, or AP-
1 (c-Jun) proteins in nuclear extracts were quantified by meas-
uring the absorbance at 450 nm on a Multiskan™ microplate
reader (Labsystems, part of Thermo Fisher Scientific Inc.,
Waltham, MA, USA). The specificity of the assay was control-
led by demonstrating that the addition of an excess of wild-
type consensus RE (20 pmol/well) prevented transcription
factor binding onto the well whereas an excess of mutated
consensus RE remained ineffective.
Statistical analysis
Data are expressed as the mean ± standard deviation of at
least three independent assays. Comparisons were made by
analysis of variance, followed by Fisher protected least-
squares difference post hoc test, using Statview™ version 5.0
software (SAS Institute Inc., Cary, NC, USA). A P value of less
than 0.05 was considered significant (*P < 0.05 versus con-
trol and #P < 0.05 versus IL-1β).
Results
1. Effect of IL-1β on the expression of RAR and RXR 
subtypes
Preliminary experiments using MTT assay showed no loss of
cell viability in rat synovial fibroblasts stimulated with IL-1β (10
ng/mL) in the presence or absence of RAR or RXR agonists at
the concentrations used (data not shown). As shown in Figure
1, the mRNAs and the proteins for all RAR subtypes (Figure
1a,b) and for RXR-α and -β (Figure 1c,d) were detected in syn-
ovial fibroblasts under basal conditions. The mRNA of RXR-γ
was not detected in our cell population, but a control experi-
ment showed that it was highly expressed in rat adipose tis-
sue, cortex, and heart (data not shown), therefore confirming
its restricted expression profile. In response to a stimulation of
6 to 24 hours with IL-1β, the mRNA levels of RAR decreased
from 30% to 55% for the -α subtype, from 15% to 60% for the
-β subtype, and from 10% to 25% for the -γ subtype (Figure
1a). Levels of mRNA of RXR-α or -β were not affected by IL-
1β stimulation (Figure 1c). Western blotting confirmed these
expression profiles at the protein level (Figure 1b,d).
2. Effect of retinoids on IL-1β-induced expression of IL-6
As shown in Figure 2, IL-6 mRNA level (Figure 2a) and corre-
sponding mediator (Figure 2b) were not detected in basal
conditions but were strongly expressed in response to IL-1β.
In IL-1-stimulated synovial fibroblasts, ATRA (RAR agonist)
decreased IL-6 gene expression from 70% (Figure 2a) and IL-
6 level from 30% (Figure 2b) compared with IL-1β controls.
This inhibition was dose-dependent for ATRA between 1 nM
and 10 μM (data not shown). In contrast, BMS-649 (RXR ago-
nist) was ineffective on IL-6 expression or production (Figure
2a,b). A costimulation with ATRA and BMS-649 inhibited
proinflammatory cytokine expression to the same extent as
ATRA alone.
3. Effect of RAR-selective agonists on IL-1-induced 
expression of IL-6
As the RXR agonist (BMS-649) was inactive on IL-1-induced
expression of IL-6 whereas the RAR agonist (ATRA) was inhib-
itory, we next investigated the contribution of the different RAR
subtypes. At the concentration used, the three selective RAR
agonists (BMS-753 for RAR-α, BMS-453 for RAR-β, and
BMS-961 for RAR-γ) increased the mRNA level of RAR-β,
chosen as an RAR-dependent target gene, from 2- to 20-fold
(Figure 3a). This demonstrated that the RAR-selective ago-
nists were active in our experimental system. A subsequent
dose-ranging study demonstrated that none of the three ago-
nists reproduced the inhibitory effect of 1 μM ATRA on IL-6
(Figure 3b). These data demonstrated that RAR subtype acti-
vation was not implied in the inhibitory effects of ATRA.
4. Effect of RAR silencing on the IL-6-suppressive effect 
of ATRA
siRNAs designed against RAR-α, RAR-β, or RAR-γ were used
to confirm whether the cytokine-suppressive effect of ATRAAvailable online http://arthritis-research.com/content/10/6/R141
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on IL-6 was RAR-independent. As shown in Figure 4a, the
transfection of synovial fibroblasts with each siRNA signifi-
cantly reduced the mRNA level of the targeted RAR subtype,
whereas the transfection of an oligomeric sequence has no
effect (Figure 4a). After 24 hours of incubation, transfected
synovial fibroblasts remained responsive to IL-1β, although the
extent of IL-6 induction was slightly lower than in non-trans-
fected cells (Figure 4b). However, whatever the RAR siRNA
used, ATRA still inhibited IL-1-induced expression of IL-6 with
an efficacy similar to that of non-transfected cells (around
70%) (Figure 4b). These data indicated that the suppressive
effect of ATRA on IL-1-induced responses was likely RAR-
independent.
5. Effect of ATRA on IL-1β-induced activation of MAPK 
pathways
In our experimental system, p38 MAPK, JNK, and ERK1/2 path-
ways were activated by IL-1β, with the phosphorylation of JNK
and p38 MAPK being obvious from 5 to 15 minutes and of
ERK1/2 from 5 to 30 minutes after IL-1β challenge (data not
shown). In these experimental conditions, ATRA affected the
early phosphorylation neither of p38 MAPK (Figure 5a) nor of
Figure 1
Effect of interleukin-1-beta (IL-1β) on the expression of retinoic acid receptor (RAR) or retinoid X receptor (RXR) subtypes in synovial fibroblasts Effect of interleukin-1-beta (IL-1β) on the expression of retinoic acid receptor (RAR) or retinoid X receptor (RXR) subtypes in synovial 
fibroblasts. Rat cells were stimulated with 10 ng/mL of IL-1β for 6, 12, or 24 hours for RAR or RXR gene expression and for 24 hours (C for control) 
for RAR or RXR protein expression. Levels of mRNA of RAR (α, β, γ) (a) or RXR (α, β, γ) (c) quantified by real-time polymerase chain reaction and 
normalized to ribosomal protein S29 (RP29) are shown. Data are expressed as mean ± standard deviation from three independent experiments. Pro-
tein expressions of RAR (α, β, γ) (b) or RXR (α, β) (d) normalized to β-actin are shown. Statistically significant differences from the control are indi-
cated as *P < 0.05.Arthritis Research & Therapy    Vol 10 No 6    Kirchmeyer et al.
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JNK (Figure 5b) induced by IL-1β. In contrast, ATRA reduced
the level of ERK1/2 phospho-proteins from 30% to 50% (Fig-
ure 5c). These data demonstrated that, among IL-1-activated
MAPK pathways, ATRA was inhibitory only on ERK1/2 in rat
synovial fibroblasts.
6. Contribution of ERK1/2 to the activation of AP-1 and 
NF-IL-6 but not of NF-κB
A control experiment showed that, at the concentration used,
PD-98059 efficiently prevented the IL-1β-induced phosphor-
ylation of ERK1/2 in our experimental system (Figure 6a). In
these conditions, the stimulating effect of IL-1β on IL-6 release
was reduced to the same extent (40% to 50%) by PD-98059
and ATRA (Figure 6b). In preliminary experiments, activation of
transcriptions factors by IL-1β was shown to be significant
after 30 minutes of stimulation for NF-κB (1.6-fold) and after 4
hours of stimulation for NF-IL-6 (5-fold) or AP-1 (c-Jun) (7-fold)
(data not shown). In IL-1β-stimulated cells, neither PD-98059
nor ATRA reduced the activation of the NF-κB pathway (Fig-
ure 6c), whereas a comparable inhibition (40% to 55%) of NF-
IL-6 (Figure 6d) or AP-1 (c-Jun) (Figure 6e) was observed with
both molecules. These data suggested that inhibition of the
ERK1/2 pathway by ATRA contributed to its inhibitory effect on
Figure 2
Effect of retinoids on interleukin-1-beta (IL-1β)-induced expression of  IL-6 in synovial fibroblasts Effect of retinoids on interleukin-1-beta (IL-1β)-induced expres-
sion of IL-6 in synovial fibroblasts. Rat cells were stimulated with 10 
ng/mL of IL-1β for 6 hours (IL-6 expression) or 24 hours (IL-6 produc-
tion) in the presence or absence of 1 μM all-trans retinoic acid (ATRA) 
(retinoic acid receptor agonist) or 0.3 μM BMS-649 (retinoid X recep-
tor agonist). (a) IL-6 mRNA levels quantified by real-time polymerase 
chain reaction and normalized to ribosomal protein S29 (RP29). (b) IL-
6 levels (nanograms per milliliter) in culture supernatant by enzyme-
linked immunosorbent assay. Data are expressed as mean ± standard 
deviation of values from at least three independent experiments. Statis-
tically significant differences from the control are indicated as *P < 
0.05 and from IL-1β-stimulated cells as #P < 0.05.
Figure 3
Effect of selective retinoic acid receptor (RAR) agonists on interleukin- 1 (IL-1)-induced expression of IL-6 Effect of selective retinoic acid receptor (RAR) agonists on inter-
leukin-1 (IL-1)-induced expression of IL-6. (a) To control the ability 
of the selective agonists to trigger RAR-dependent responses, rat syn-
ovial fibroblasts were stimulated for 6 hours with 0.1 μM of RAR ago-
nist (BMS-753 for RAR-α, BMS-453 for RAR-β, or BMS-961 for RAR-
γ), and the mRNA level of the target gene RAR-β normalized to ribos-
omal protein S29 (RP29) was studied by real-time polymerase chain 
reaction (PCR). (b) The suppressive effect of RAR-selective agonists 
on the IL-6 mRNA level normalized to RP29 was studied by real-time 
PCR in cells stimulated with 10 ng/mL of IL-1β in the presence or 
absence of 0.1 or 1 μM of RAR agonist. Data are expressed as mean ± 
standard deviation of values from at least three independent experi-
ments. Statistically significant differences from the control are indicated 
as *P < 0.05.Available online http://arthritis-research.com/content/10/6/R141
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IL-1-induced activation of NF-IL-6 and AP-1 and subsequent
production of IL-6.
Discussion
In the present work, we demonstrated for the first time that
RAR and RXR subtypes were expressed in rat synovial fibrob-
lasts at either the mRNA or the protein level. All receptor sub-
types, except RXR-γ, were detected and this was consistent
with the recent demonstration that their mRNAs, except the
RXR-γ  mRNA, were expressed in human osteoarthritic
chondrocytes [25]. In response to IL-1 stimulation, the expres-
sion of all RAR subtypes decreased in synovial fibroblasts,
whereas those of RXR-α and RXR-β remained unaffected.
However, such inhibitory effect of IL-1 may be counterbal-
anced in the presence of RAR agonist since all RAR subtypes
contain a retinoic acid response element (RARE) in their pro-
moter region [26], which renders them highly inducible by
these agonists. In our experimental conditions, we observed
that ATRA induced a threefold increase in RAR mRNA levels
in IL-1-stimulated cells (data not shown), therefore suggesting
that our biological system was suitable to study the pharmaco-
logical properties of agonists of RAR or RXR subtypes.
In IL-1-stimulated synovial fibroblasts, we demonstrated that
ATRA reduced the IL-1-induced expression and release of IL-
6 whereas the RXR agonist, BMS-649, was ineffective. For
Figure 4
Effect of retinoic acid receptor (RAR) silencing on the suppressive effect of all-trans retinoic acid (ATRA) on interleukin-6 (IL-6) expression Effect of retinoic acid receptor (RAR) silencing on the suppressive effect of all-trans retinoic acid (ATRA) on interleukin-6 (IL-6) expression. 
(a) Normalized mRNA levels of RAR-α, -β, or -γ in rat synovial fibroblasts transfected for 24 hours with 50 nM of small interfering RNA (siRNA) 
against the corresponding RAR subtype or with 50 nM of an oligonucleotidic sequence (OS), before stimulation with 1 μM ATRA for 6 hours. (b) 
Normalized mRNA levels of IL-6 in synovial fibroblasts transfected for 24 hours with 50 nM of each RAR siRNA and then stimulated for 6 hours with 
10 ng/mL of IL-1β in the presence or absence of 1 μM ATRA. Data are expressed as mean ± standard deviation of values from at least three inde-
pendent experiments. Statistically significant differences from the control are indicated as *P < 0.05 and from IL-1β-stimulated cells as #P < 0.05. 
RP29, ribosomal protein S29.Arthritis Research & Therapy    Vol 10 No 6    Kirchmeyer et al.
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the RAR agonist, this result was consistent with its ability to
reduce cytokine production by fibroblastic cells [27] or macro-
phages [28] challenged with various inflammatory stimuli. In
the case of RXR agonist, the lack of efficacy of BMS-649 was
not unexpected even if RXR agonists are well known to act as
co-stimulators and were shown to potentiate the effect of
PPAR (peroxisome proliferator-activated receptor) [29] or
RAR [30] agonists rather than to display intrinsic anti-inflam-
matory properties. However, we also failed to demonstrate any
potentiation of the suppressive effect of ATRA on IL-6 when it
was used in combination with BMS-649, suggesting that acti-
vation of RXR played a minor role. As a consequence, ATRA
could reduce IL-6 expression by activating RAR/RAR
homodimers, which were shown to exist albeit less abundantly
than RAR/RXR heterodimers [31], or by RAR-independent
mechanisms. Complementary experiments with selective ago-
nists of each RAR subtype (BMS-753 for RAR-α, BMS-453
for RAR-β, and BMS-961 for RAR-γ), or with RAR designed
against siRNA, demonstrated that the suppressive effect of
ATRA on IL-6 was RAR-independent in our cell type.
To search for signalling events able to drive the suppressive
effect of ATRA on IL-6, we investigated the possible contribu-
tion of upstream MAPKs thought to be responsive to IL-1. We
demonstrated that, as expected from the fibroblastic pheno-
type of our cell type, p38 MAPK [32] and JNK [33] were acti-
vated in response to IL-1 challenge. However, we further
showed that activation of neither of these pathways was inhib-
ited by ATRA. As a reduced phosphorylation of p38 was
thought to contribute to the inhibitory effect of ATRA on IL-1-
induced expression of cytokines in chondrocytes [34], these
data highlight that ATRA may act in a cell-dependent manner.
In contrast, we showed that phosphorylation of ERK1/2 was an
early IL-1-mediated event in rat synovial fibroblasts and dem-
onstrated that it was reduced significantly by ATRA. Activation
of ERK1/2 was also reported in mouse [35] and RA [36] syno-
vial fibroblasts challenged with IL-1 and this was shown to
contribute to the production of IL-6 in response to inflamma-
tory stimuli. In our experimental system, the MEK1 inhibitor PD-
98059 reproduced the suppressive effect of ATRA on IL-6 at
a concentration actively preventing the phosphorylation of
Figure 5
Effect of all-trans retinoic acid (ATRA) on interleukin-1-beta (IL-1β)-induced activation of MAPK pathways in rat synovial fibroblasts Effect of all-trans retinoic acid (ATRA) on interleukin-1-beta (IL-1β)-induced activation of MAPK pathways in rat synovial fibroblasts. (a) 
Phospho-JNK (P-JNK) levels after 15 minutes of stimulation with 10 ng/mL of IL-1β in the presence or absence of 1 μM ATRA. (b) Phospho-p38 
MAPK (P-p38 MAPK) levels after 5 minutes of stimulation with 10 ng/mL of IL-1β in the presence or absence of 1 μM ATRA. (c) Phospho-ERK1/2 (P-
ERK1/2, or P-p42/44) levels after 30 minutes of stimulation with 10 ng/mL of IL-1β in the presence or absence of 1 μM ATRA. Data are expressed in 
arbitrary units (AU) as mean ± standard deviation of protein levels normalized to β-actin collected from at least three independent experiments. Sta-
tistically significant differences from the control are indicated as *P < 0.05 and from IL-1β-stimulated cells as #P < 0.05. ERK1/2, extracellularly regu-
lated kinase 1/2; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; SAPK, stress-activated protein kinase.Available online http://arthritis-research.com/content/10/6/R141
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Figure 6
Contribution of ERK1/2 pathway to the inhibitory effect of all-trans retinoic acid (ATRA) Contribution of ERK1/2 pathway to the inhibitory effect of all-trans retinoic acid (ATRA). Rat synovial fibroblasts were stimulated with 10 ng/mL 
of interleukin-1-beta (IL-1β) in the presence or absence of the ERK1/2 inhibitor PD-98059 or ATRA. (a) Western blotting of phosphorylated ERK1/2 
(P-ERK1/2) after 15 minutes of stimulation in the presence or absence of 10 μM PD-98059. (b) Production of IL-6 (nanograms per milliliter by 
enzyme-linked immunosorbent assay [ELISA]) in culture supernatant after 24 hours of stimulation in the presence or absence of 10 μM PD-98059 or 
1 μM ATRA. (c) Nuclear content of nuclear factor-kappa-B (NF-κB) by ELISA-based TransAm™ kit after 30 minutes of stimulation in the presence or 
absence of 10 μM PD-98059 or 1 μM ATRA. Nuclear content of nuclear factor of interleukin-6 (NF-IL-6) (d) or activator protein-1 (AP-1) (c-Jun) (e) 
by ELISA-based TransAm™ kit after 4 hours of stimulation in the presence or absence of 10 μM PD-98059 or 1 μM ATRA. Data are expressed as 
mean ± standard deviation of IL-6 levels or absorbance value at 450 nm values from at least three independent experiments. Statistically significant 
differences from the control are indicated as *P < 0.05 and from IL-1β-stimulated cells as #P < 0.05. ERK1/2, extracellularly regulated kinase 1/2.Arthritis Research & Therapy    Vol 10 No 6    Kirchmeyer et al.
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ERK1/2. Taken together, these data strongly suggested that
the inhibition of the ERK1/2 pathway by ATRA supported its
suppressive effect on IL-1-induced production of IL-6.
The transcription factors NF-IL-6, AP-1, and NF-κB possess
binding sites in the promoter of IL-6 but their respective con-
tributions to the stimulating effect of IL-1 on IL-6 expression
seem to be variable in RA synovial fibroblasts [37,38]. In our
system, we demonstrated that IL-1 activated NF-IL-6, AP-1,
and NF-κB pathways although with a different kinetics. Kinet-
ics may explain some discrepancy between the published data
with human cells since we confirmed a lack of activation of NF-
IL-6 or c-Jun after 30 minutes of stimulation with IL-1 [37] but
a strong activation of both pathways after 4 hours of stimula-
tion [38]. At the time of their optimal activation, we demon-
strated that ATRA suppressed NF-IL-6 and AP-1 pathways but
not NF-κB pathway and this effect was reproduced by the
ERK1/2 inhibitor PD-98059. In contrast, the inhibitory effect of
PD-98059 showed that AP-1 was activated by ERK1/2 in syn-
ovial fibroblasts [39,40] and could contribute to the enhanced
production of IL-6 in response to IL-1 [38]. This result was
highly consistent with the regulation of MMP-1 by IL-1 in rabbit
synovial fibroblasts, where the ERK1/2, but not the p38, path-
way accounted for the phosphorylation and activation of c-Jun
[39]. The third transcription factor, NF-IL-6, can be activated
by a lot of biological signals but contains a highly conserved
phosphorylation site for MAPKs [41], which regulates its
nuclear translocation in response to growth factors [42]. Our
data demonstrated that activation of NF-IL-6 depended on
activation of ERK1/2, as was reported for the differentiating
effect of adiponectin on preadipocyte fibroblasts [43]. Such
blockade of NF-IL-6 by PD-98059 inducing the inhibition of IL-
6 levels was shown in Kaposi sarcoma cells [44]. Thus, we
provide evidence that ERK1/2 contributed to the IL-1-induced
activation of AP-1 and NF-IL-6 in synovial fibroblasts. In addi-
tion, our data suggest that the suppressive effect of ATRA on
these transcription factors may be supported by inhibition of
ERK1/2 phosphorylation. This mechanism is consistent with the
ability of retinoids to mediate most of their anti-inflammatory
effects by reducing activation of the AP-1 (for a review, see
[45]) or NF-IL-6 [44] pathways, although it remains to be con-
firmed in other cell types.
Conclusion
The present work demonstrated that ATRA, but several selec-
tive RAR agonists, displayed a powerful inhibitory potency on
IL-1-induced expression and release of IL-6 by synovial fibrob-
lasts. Despite the presence of all RAR and RXR subtypes,
except RXR-γ, this suppressive effect was RAR-independent
and not sensitive to RXR activation. Among MAPKs, ATRA
reduced the phosphorylation of ERK1/2 and the activation of
AP-1 and NF-IL-6 pathways, but not of NF-κB. These effects
were reproduced by the MEK1 inhibitor PD-98059, suggest-
ing that inhibition of the ERK1/2 pathway supported the sup-
pressive potency of ATRA on transcription factors and IL-6
release. The present data underline that a decreased synthesis
of IL-6 by synovial fibroblasts can contribute to the anti-arthritic
potency of ATRA in animal models, as was suggested for the
inhibitory effect of Am-80 in human osteoblast-like cells [46].
Nonetheless, this cytokine-suppressive potency was inde-
pendent of RAR, indicating that alternative mechanisms, such
as modulation of histone deacetylase activity [39], or retinoyla-
tion of kinases upstream of the ERK1/2 pathway [47,48] could
support the anti-inflammatory effect of other retinoids.
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